New bispecific drug targets Hard-to-Treat cancers in early trial
NCT ID NCT06840119
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called IMC-R117C, alone or with other cancer drugs, in people with advanced colorectal, esophageal, stomach, or ovarian cancers that have a specific genetic marker (HLA-A*02:01) and produce a protein called PIWIL1. The trial aims to find safe doses and check if the drug can shrink tumors. About 600 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IMC-R117C (a bispecific protein that targets cancer cells and immune cells)
What this could lead to
If successful, this could lead to a new treatment option for certain advanced cancers that have not responded to standard therapies.
What could go wrong
This is an early first-in-human trial, so safety and effectiveness are not yet known. The drug may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Antoni van Leeuwenhoek
RECRUITINGAmsterdam, Netherlands
-
Centro Integral Oncologico Clara Campal
RECRUITINGMadrid, Spain
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
RECRUITINGRoma, Italy
-
Hospital HM Nou Delfos
RECRUITINGBarcelona, Spain
-
Hospital Universitario Fundacion Jimenez Diaz
RECRUITINGMadrid, Spain
-
Institut Jules Bordet
RECRUITINGAnderlecht, 1070, Belgium
-
Peter MacCallum Cancer Centre
RECRUITINGMelbourne, Australia
-
St Vincent's Hospital
ACTIVE_NOT_RECRUITINGDarlinghurst, Sydney, NSW 2010, Australia
-
UZ Leuven
RECRUITINGLeuven, 3000, Belgium
-
Universitaetsklinikum Heidelberg
RECRUITINGHeidelberg, Germany
-
Universitair Ziekenhuis Gent
RECRUITINGGhent, Belgium
-
VHIO, Vall d'Hebron University Hospital
RECRUITINGBarcelona, Spain
-
nstituto Clinico Humanitas
RECRUITINGRozzano, 20089, Italy